Cryo Cell International (CCEL) Cash & Equivalents (2010 - 2026)

Cryo Cell International has disclosed Cash & Equivalents across 17 years of filings, most recently posting $249672.0 for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 11.9% year-over-year to $249672.0; the TTM figure through Feb 2026 stood at $249672.0 (up 11.9% YoY), while the FY2025 annual figure was $319031.0, down 43.13% from the prior year.
• Cash & Equivalents slipped to $249672.0 in Q1 2026, from $319031.0 in the prior quarter.
• Over the last five years, Cash & Equivalents for CCEL reached as high as $2.9 million in Q3 2022 and fell as low as $137491.0 in Q2 2025.
• The 5-year median for Cash & Equivalents is $469195.0 (2024), against an average of $925536.7.
• The widest YoY moves for Cash & Equivalents: up 38.14% in 2024, down 82.0% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $1.7 million in 2022, then slumped by 76.17% to $406067.0 in 2023, then soared by 38.14% to $560960.0 in 2024, then tumbled by 43.13% to $319031.0 in 2025, then declined by 21.74% to $249672.0 in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $249672.0, $319031.0, and $265207.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.